CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 59 enrolled
Drug / intervention
Zoledronic Acid +2 moredrug
Likely dose
Zoledronic Acid 4mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00580047
NCT00580047N/ACompleted
CompareCT.gov

Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplant

University of Nebraska·interventional·Posted Dec 24, 2007·Updated Oct 4, 2023

In Brief

A clinical study evaluating Zoledronic Acid, Calcium with vitamin D, and 1 other intervention for Renal Insufficiency. Completed, enrolled 59 participants across 1 site.

Detailed Summary

The study is designed to look at the effect of different bone treatment plans on bone loss after kidney or kidney/pancreas transplant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Insufficiency
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 24, 2007
Enrollment StartDec 1, 2003
Primary CompletionJul 29, 2014
TodayJul 2, 2026
Enrollment to primary: 10.7 yearsPosted 18.5 years ago

Interventions

Zoledronic Aciddrug

4mg IV Annually

Calcium with vitamin Dcombination

1200 mg Calcium with 800 International Units of vitamin D

Alendronatedrug

70mg weekly